Mon, October 24, 2022
Fri, October 21, 2022
Thu, October 20, 2022

Colin Bristow Maintained (VRTX) at Strong Buy with Increased Target to $337 on, Oct 21st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-337-on-oct-21st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Colin Bristow of UBS, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $335 to $337 on, Oct 21st, 2022.

Colin has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 5 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $276 on, Friday, September 2nd, 2022
  • Do Kim of "Piper Sandler" Maintained at Hold with Increased Target to $288 on, Wednesday, August 17th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold and Held Target at $263 on, Wednesday, August 10th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $253 on, Monday, August 8th, 2022
  • Brian Skorney of "Baird" Maintained at Hold and Held Target at $250 on, Friday, August 5th, 2022


These are the ratings of the 3 analyists that currently disagree with Colin


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $300 on, Friday, August 5th, 2022
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $307 on, Friday, August 5th, 2022
  • Olivia Brayer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $365 on, Wednesday, July 13th, 2022

Publication Contributing Sources